Stocks and Investing
Stocks and Investing
Fri, March 1, 2024
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
Thu, February 29, 2024
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
Whitney Ijem Reiterated (BMRN) at Hold and Held Target at $91 on, Feb 29th, 2024
Whitney Ijem of Canaccord Genuity, Reiterated "BioMarin Pharmaceutical Inc." (BMRN) at Hold and Held Target at $91 on, Feb 29th, 2024.
Whitney has made no other calls on BMRN in the last 4 months.
There are 8 other peers that have a rating on BMRN. Out of the 8 peers that are also analyzing BMRN, 1 agrees with Whitney's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Luca Issi of "RBC Capital" Reiterated at Hold and Held Target at $100 on, Friday, February 23rd, 2024
These are the ratings of the 7 analyists that currently disagree with Whitney
- Christopher Raymond of "Piper Sandler" Maintained at Buy with Decreased Target to $107 on, Friday, February 23rd, 2024
- Olivia Brayer of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $100 on, Friday, February 23rd, 2024
- Joel Beatty of "Baird" Maintained at Buy with Decreased Target to $104 on, Tuesday, January 30th, 2024
- Paul Matteis of "Stifel" Reiterated at Strong Buy and Held Target at $101 on, Thursday, December 21st, 2023
- Kostas Biliouris of "BMO Capital" Maintained at Buy with Decreased Target to $100 on, Friday, November 3rd, 2023
- Gena Wang of "Barclays" Maintained at Buy with Decreased Target to $111 on, Thursday, November 2nd, 2023
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $117 on, Thursday, November 2nd, 2023
Contributing Sources